Vivimed Labs Secures Court Protection Amid CBI Fraud Investigation

A pharmaceutical company under investigation by India's Central Bureau of Investigation has obtained emergency court protection that halts federal proceedings and prevents its accounts from being declared fraudulent by the country's largest bank. Vivimed Labs Limited secured an interim stay from the Telangana High Court on February 6, 2026, providing temporary relief from both the CBI case and potential sanctions from State Bank of India.

The intervention comes months after federal agents registered a criminal case against the company and four of its directors, alleging violations including criminal conspiracy, forgery, and corruption offenses. The court's order maintains the status quo until further judicial review, effectively pausing one of India's most significant banking fraud investigations of 2026.

Background and Context

The CBI's investigation, registered as case number RC 03(E)/2025/CBI/BSFB/BLR on November 19, 2025, represents part of India's intensified crackdown on corporate financial crime. The case involves allegations under multiple sections of the Indian Penal Code—including criminal conspiracy (120-B), cheating (420), and forgery (468, 471)—as well as provisions of the Prevention of Corruption Act, 1988.

Federal investigators conducted search and seizure operations at Vivimed Labs premises on January 20, 2026, following which the company's Chief Financial Officer and Company Secretary received formal notices from the CBI's Banking Securities Fraud Branch in Bengaluru. The investigation focuses on alleged financial irregularities that could impact the company's ability to maintain its lending relationships with major banking institutions.

Key Figures and Entities

According to corporate disclosures and court documents, the CBI case names Vivimed Labs Limited as the primary accused alongside four of its directors, though the individuals are not specifically identified in publicly available filings. The company, headquartered in Hyderabad with manufacturing operations in Karnataka, trades on both the Bombay Stock Exchange (code: 532660) and National Stock Exchange (symbol: VIVIMEDLAB).

The Telangana High Court for the state of Telangana at Hyderabad granted the interim stay order through its proceedings, marking a significant judicial intervention in an ongoing federal investigation. State Bank of India, India's largest public sector bank, was reportedly preparing to declare Vivimed Labs' account as fraudulent before the court's intervention.

Legal and Financial Mechanisms

The High Court's comprehensive stay order, dated February 6, 2026 and formally received by the company on February 9, 2026, provides multi-layered protection. According to Vivimed Labs' disclosures to securities regulators, the order restrains all proceedings arising from the January search operations, prevents coercive actions against the company and its directors, and specifically blocks SBI from declaring the company's account as fraudulent.

This legal maneuver effectively preserves the company's access to banking services while the underlying criminal allegations remain unresolved. The case highlights the complex interplay between criminal investigations and civil banking regulations in India's financial system, where fraud declarations can trigger immediate operational consequences for businesses.

International Implications and Policy Response

The Vivimed Labs case occurs against the backdrop of India's evolving regulatory framework for corporate governance and financial crime prevention. The Securities and Exchange Board of India's Listing Obligations and Disclosure Requirements (LODR) 2015 governs how listed companies must disclose material developments, with Vivimed having complied through announcements on February 3 and February 9, 2026.

The situation underscores ongoing challenges in India's efforts to strengthen corporate accountability while ensuring due process rights. Legal experts note that the use of interim stays in high-profile financial crime cases raises questions about the balance between investigative urgency and judicial oversight in complex commercial disputes involving multiple regulatory agencies.

Sources

This report draws on corporate disclosures filed with Indian securities regulators, court records from the Telangana High Court, and official CBI case documentation. Additional information was obtained from regulatory compliance announcements submitted to the Bombay Stock Exchange and National Stock Exchange between November 2025 and February 2026.